

0/25/99



K984545  
**PHILIPS**

**Philips Medical Systems**

**510(k) Summary**

Company name: Philips Medical Systems North America Company

Address: 710 Bridgeport Avenue  
Shelton, CT 06484

Contact person: P. Altman

Telephone number: 203-926-7031

Prepared: December 21, 1998

Device name: **Philips Integris Series Release 2 systems**

Classification name: Angiographic X-ray system, 21 CFR 892.1600  
Class II (90 IZI)

Common/Usual name: Angiographic x-ray system

Predicate Device(s): Philips Integris V5000 and H5000

RECEIVED  
 22 FEB 11 1999  
 FDA/CDRH/OBE/DAC

**Intended use:**

The **Philips Integris Series Release 2** systems are intended for use in acquiring diagnostic quality images during cardiac, angiographic, vascular, neurovascular, and interventional applications.

**System description:**

The Philips Integris Series Release 2 systems include the Integris H5000, BH5000, V5000, BV5000, and HM2000. These systems are fully integrated, single and biplane, cath labs.

**Safety / Software Information**

An overview of the software description, the design, the summary of hazard analysis results and technical and safety information was included. The systems are designed in compliance with the applicable sections of Title 21 CFR part 1020, UL 187 and 2601, and comply with the ACR/NEMA DICOM digital imaging communication standard.

AK-5

Philips Medical Systems  
 North America Company  
 710 Bridgeport Avenue  
 P.O. Box 860  
 Shelton, Connecticut 06484-0917  
 Tel: (203) 926-7674  
 Fax: (203) 929-6099



FEB 25 1999

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Peter Altman  
Director of Regulatory Affairs  
Philips Medical Systems  
North America Company  
710 Bridgeport Avenue  
P.O. Box 860  
Shelton, Connecticut 06484-0917

Re: K984545  
Philips Integris Series Release 2 Systems  
Dated: December 21, 1998  
Received: December 22, 1998  
Regulatory class: II  
21 CFR 892.1600/Procode: 90 IZI

Dear Mr. Altman:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

  
Capt. Daniel G. Schultz, M.D.  
Acting Director, Division of Reproductive,  
Abdominal, Ear, Nose and Throat,  
and Radiological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

510(k) Number (if known): K984545

Device Name : Philips Integris Systems, Release 2

Indications For Use :

The **Philips Integris Series Release 2** systems are intended for use in acquiring diagnostic quality images during cardiac, angiographic, vascular, neurovascular, and interventional applications.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

David G. Ferguson  
(Division Sign-Off)  
Division of Reproductive, Abdominal, ENT,  
and Radiological Devices  
510(k) Number K984545

Prescription Use              
( Per 21 CFR 801.109

OR

Over-The-Counter Use